# Exploring Clinical Trials of Peptides in Amyotrophic Lateral Sclerosis (ALS)

Canonical source: https://retacompare.com/research/clinical-trial-landscape-for-peptides-in-amyotrophic-lateral-sclerosis-als

Peptides for Disease — Clinical Trials · 2026-05-03


    This article reviews the clinical trial landscape for peptides in the context of Amyotrophic Lateral Sclerosis (ALS), highlighting ongoing research, anecdotal reports, and the current state of clinical evidence.

 The big picture

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. The disease leads to muscle weakness, atrophy, and ultimately respiratory failure. While the exact cause of ALS remains unclear, research is ongoing to explore various treatment options, including the use of peptides. Peptides are short chains of amino acids that can have various biological effects, and their potential role in ALS is being investigated in several clinical trials. This article focuses on the current clinical trial landscape for peptides in ALS, examining both the scientific evidence and anecdotal reports from the community. For broader context, see our peptide stacking guide.

 What the clinical evidence shows

Currently, the clinical evidence for the use of peptides in ALS is limited and largely hypothesis-driven. Some peptides, such as insulin-like growth factor 1 (IGF-1) analogs, have been studied for their neuroprotective properties. Clinical trials have explored the effects of IGF-1 in ALS, but results have been mixed, and further research is necessary to establish its efficacy. Additionally, preclinical studies have suggested potential benefits of semaglutide, a GLP-1 receptor agonist, in neurodegenerative diseases, including ALS. However, these findings are still in early stages and require further exploration in controlled trials. Another peptide, Cerebrolysin, has been reported to have neuroprotective effects and is approved in several countries outside the US. However, it has not received FDA approval for ALS, and controlled clinical data in the US remains sparse. Overall, while some peptides are being studied for their potential benefits in ALS, robust clinical evidence is still lacking.

 What the community reports anecdotally

Anecdotal reports from the community regarding the use of peptides for ALS management are prevalent, particularly in online forums and biohacker circles. Users often discuss their experiences with peptides like BPC-157, TB-500, and GHK-Cu, claiming various benefits such as improved muscle strength and reduced symptoms. However, it is essential to note that these reports are self-reported and lack controlled trial data to substantiate their claims. No clinical trials have confirmed the efficacy of these peptides for ALS, and such anecdotal evidence should be approached with caution. The absence of FDA approval for these peptides further underscores the need for rigorous scientific validation.

 Key points at a glance

ALS is a progressive neurodegenerative disease with no known cure.

Peptides are being investigated for their potential neuroprotective effects in ALS.

Current clinical evidence for peptides in ALS is limited and primarily hypothesis-driven.

IGF-1 analogs and semaglutide are among the peptides being studied.

Anecdotal reports exist but lack controlled clinical validation.

Many peptides discussed are not FDA-approved for ALS or any indication.

Further research is needed to establish the efficacy and safety of peptides in ALS.

 Safety and what to watch for

The use of peptides for ALS and other conditions can carry risks, especially when used off-label or without medical supervision. Side effects may vary depending on the peptide and individual patient factors. For instance, some users report injection site reactions, gastrointestinal disturbances, or other adverse effects. Additionally, the lack of regulatory oversight for many research peptides means that quality control can be inconsistent, leading to potential contamination or mislabeling. It is crucial for individuals considering peptide therapy to consult with qualified healthcare professionals to understand the risks and benefits involved.

 Open questions

Despite ongoing research, many questions remain regarding the use of peptides in ALS. Key areas of uncertainty include the optimal dosing regimens, long-term safety, and the mechanisms by which these peptides may exert effects on neurodegeneration. Furthermore, the regulatory landscape for peptides is complex, with many remaining unapproved by the FDA. Future studies will need to address these gaps and provide clearer guidance on the role of peptides in managing ALS.

 Bottom line

While peptides are being explored for their potential roles in ALS treatment, current clinical evidence is limited, and anecdotal reports should be interpreted cautiously. Continued research is necessary to clarify their efficacy and safety in this challenging disease.

 This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Amyotrophic Lateral Sclerosis (ALS) or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources